PER® Postgame™: MS Meeting Updates – Integrating the Latest Data to Optimize Care in the COVID-19 Era

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe currently available molecular biomarkers/other key indicators of MS and their role in early differential diagnosis and monitoring disease progression
• Evaluate recent efficacy and safety data of current and emerging DMTs for the optimal treatment of patients with MS
• Discuss the impact of DMTs on anti-SARS-CoV-2 vaccine response in patients with MS
• Implement timely, evidence-based strategies to maximize immune response to anti-SARS-CoV-2 immunotherapy in patients with MS exposed or infected with SARS-CoV-2
• Design COVID-19 prevention/treatment plans that minimize risk of SARS-CoV-2 infection while maintaining efficacy of DMTs in patients with MS